Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients

Clinical Cancer Research

Volumn 10, Issue 16, 2004, Pages 5391-5402

  Mosolits, Szilvia ^a   Markovic, Katja ^a   Frödin, Jan Erik ^a   Virving, Lena ^a   Magnusson, Carl G M ^b   Steinitz, Michael ^c   Fagerberg, Jan ^a   Mellstedt, Håkan ^a,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Angelholm Hospital   (Sweden)

^c HEBREW UNIVERSITY   (Israel)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; EPITHELIAL CELL ADHESION MOLECULE; EPITOPE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; THYROID HORMONE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BLISTER; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DIARRHEA; DRUG SAFETY; EDEMA; ENZYME LINKED IMMUNOSPOT ASSAY; ERYTHEMA; FATIGUE; FEMALE; FLOW CYTOMETRY; FLU LIKE SYNDROME; HASHIMOTO DISEASE; HUMAN; HUMORAL IMMUNITY; HYPESTHESIA; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE; IRRITABILITY; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALE; MOOD DISORDER; MYALGIA; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN MANIFESTATION; T LYMPHOCYTE; TH1 CELL; VACCINATION;

AGED; AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL ADHESION MOLECULES; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; EPITOPES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOGLOBULIN G; MALE; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; PEPTIDE FRAGMENTS; RECTAL NEOPLASMS;

EID: 4143069181     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0425     Document Type: Article

References (44)

1. Tebbutt NC, Cattell E, Midgley R, Cunningham D, Kerr D. Systemic treatment of colorectal cancer. Eur J Cancer 2002;38:1000-15.
2. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999;77:699-712.
3. Mosolits S, Steinitz M, Harmenberg U, et al. Immunogenic regions of the GA733-2 tumour-associated antigen recognised by autoantibodies of patients with colorectal carcinoma. Cancer Immunol Immunother 2002;51:209-18.
4. Nagorsen D, Keilholz U, Rivoltini L, et al. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res 2000;60:4850-4.
5. Riethmuller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16:1788-94.
6. Punt CJ, Nagy A, Douillard JY, et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002; 360:671-7.
7. Fields A, Keller A, Schwartzberg L, et al. Edrecolomab (17-1A antibody) in combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomized North American phase III study. Proc Am Soc Clin Oncol 2002; 21:128a.
8. Basak S, Eck S, Gutzmer R, et al. Colorectal cancer vaccines: antiidiotypic antibody, recombinant protein, and viral vector. Ann N Y Acad Sci 2000;910:237-52; discussion 252-3.
9. Ullenhag GJ, Frodin JE, Mosolits S, et al. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony-stimulating factor induced a tumor-specific cellular immune response. Clin Cancer Res 2003;9:2447-56.
10. Staib L, Birebent B, Somasundaram R, et al. Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients. Int J Cancer 2001; 92:79-87.
11. Bhattacharya-Chatterjee M, Chatterjee SK, Foon KA. Anti-idiotype vaccine against cancer. Immunol Lett 2000;74:51-8.
12. Fagerberg J, Steinitz M, Wigzell H, Askelof P, Mellstedt H. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci USA 1995;92:4773-7.
13. Mellstedt H, Fagerberg J, Frodin JE, et al. Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors. Curr Opin Hematol 1999; 6:169-75.
14. Birebent B, Somasundaram R, Purev E, et al. Anti-idiotypic antibody and recombinant antigen vaccines in colorectal cancer patients. Crit Rev Oncol Hematol 2001;39:107-13.
15. Bhattachary-Chatterjee M, Nath Baral R, Chatterjee SK, et al. Counterpoint. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine. Cancer Immunol Immunother 2000;49:133-41.
16. Jager E, Jager D, Knuth A. Antigen-specific immunotherapy and cancer vaccines. Int J Cancer 2003;106:817-20.
17. Clay TM, Hobeika AC, Mosca PJ, Lyerly HK, Morse MA. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res 2001;7:1127-35.
18. Widhe M, Ekerfelt C, Forsberg P, Bergstrom S, Ernerudh J. IgG subclasses in Lyme borreliosis: a study of specific IgG subclass distribution in an interferon-gamma-predominated disease. Scand J Immunol 1998;47:575-81.
19. Strassburg CP, Kasai Y, Seng BA, et al. Baculovirus recombinant expressing a secreted form of a transmembrane carcinoma-associated antigen. Cancer Res 1992;52:815-21.
20. Steinitz M, Tamir S, Frodin JE, Lefvert AK, Mellstedt H. Human monoclonal anti-idiotypic antibodies. I. Establishment of immortalized cell lines from a tumor patient treated with mouse monoclonal antibodies. J Immunol 1988;141:3516-22.
21. Fagerberg J, Frodin JE, Ragnhammar P, et al. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy? Cancer Immunol Immunother 1994;38:149-59.
22. Samanci A, Yi Q, Fagerberg J, et al. Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer Immunol Immunother 1998;47:131-42.
23. Szala S, Froehlich M, Scollon M, et al. Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc Natl Acad Sci USA 1990;87:3542-6.
24. Fagerberg J. Structural and immunological characterization of human anti-idiotypic antibodies used for immunization of colorectal carcinoma patients. In: Fagerberg J. The idiotypic network response in cancer patients treated with monoclonal antibodies (Doctoral dissertation). Stockholm, Sweden: Karolinska Institutet; 1995. ISBN 91-628-1625-X.
25. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics 1999;50:213-9.
26. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75.
27. Ras E, van der Burg SH, Zegveld ST, et al. Identification of potential HLA-A*0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). Hum Immunol 1997;53:81-9.
28. Magnusson CG, Nelson DF, Magnusson MA. Disproportional distribution of isotype and non-isotype-specific IgG subclass anti-IgE autoantibodies in human cord serum. Int Arch Allergy Immunol 1996; 110:31-40.
29. Vial T, Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology 1995;105:31-57.
30. Papadea C, Check IJ. Human immunoglobulin G and immunoglobulin G subclasses: biochemical, genetic, and clinical aspects. Crit Rev Clin Lab Sci 1989;27:27-58.
31. Tomee JF, Dubois AE, Koeter GH, et al. Specific IgG4 responses during chronic and transient antigen exposure in aspergillosis. Am J Respir Crit Care Med 1996; 153:1952-7.
32. Brewer JM, Conacher M, Hunter CA, et al. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol 1999;163: 6448-54.
33. Ullenhag GJ, Frodin JE, Strigard K, Mellstedt H, Magnusson CG. Induction of IgG subclass responses in colorectal carcinoma patients vaccinated with recombinant carcinoembryonic antigen. Cancer Res 2002;62:1364-9.
34. Derby EG, Reddy V, Nelson EL, et al. Correlation of human CD56+ cell cytotoxicity and IFN-gamma production. Cytokine 2001; 13:85-90.
35. Ghanekar SA, Nomura LE, Suni MA, et al. Gamma interferon expression in CD8(+) T cells is a marker for circulating cytotoxic T lymphocytes that recognize an HLA A2-restricted epitope of human cytomegalovirus phosphoprotein pp65. Clin Diagn Lab Immunol 2001; 8:628-31.
36. Arina A, Tirapu I, Alfaro C, et al. Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. Exploiting crosspriming. Exp Hematol 2002;30:1355-64.
37. Somasundaram R, Zaloudik J, Jacob L, et al. Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody. J Immunol 1995;155:3253-61.
38. Trojan A, Witzens M, Schultze JL, et al. Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule. Cancer Res 2001;61:4761-5.
39. Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P. Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol 2000;164: 1148-52.
40. Santin AD, Hermonat PL, Ravaggi A, et al. Expression of CD56 by human papillomavirus E7-specific CD8 + cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells. Clin Cancer Res 2001;7(suppl):804s-10s
41. Carding SR, Egan PJ. Gammadelta T cells: functional plasticity and heterogeneity. Nat Rev Immunol 2002;2:336-45.
42. Knutson KL, Disis ML. Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient. Hum Immunol 2002;63: 547-57.
43. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003;21:483-513.
44. Gillessen S, Naumov YN, Nieuwenhuis EE, et al. CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc Natl Acad Sci USA 2003;100:8874-9.